To further assess the potential effectiveness of these inhibitors in preclinical models, we first treated bone marrow cells from four different patients with indolent and smoldering mastocytosis (see Table S1 in Supplementary Material) with SPHK1-1 or SPHK2-I. The gene discussed is SPHK2; the disease is mastocytosis.